SS
ACRV icon

SBI Securities’s Acrivon Therapeutics ACRV Stock Holding History

SBI Securities’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$134 Buy
75
+1
+1% +$2 ﹤0.01% 3436
2026
Q1 		$103 Hold
74
– – ﹤0.01% 3396
2025
Q4 		$178 Hold
74
– – ﹤0.01% 3244
2025
Q3 		$134 Hold
74
– – ﹤0.01% 3431
2025
Q2 		$88 Hold
74
– – ﹤0.01% 3573
2025
Q1 		$150 Hold
74
– – ﹤0.01% 3310
2024
Q4 		$445 Buy
+74
New +$538 ﹤0.01% 2936

Other funds holding ACRV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AWM
AAF Wealth Management Westborough, Massachusetts $271M AUM 24.26% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

SBI Securities's ACRV Position: Q2 2026 in Review

SBI Securities increased its Acrivon Therapeutics (ACRV) stake by 1.4% in Q2 2026, buying an estimated $2 and bringing the position to 75 shares worth $134. The position accounts for ﹤0.01% of the portfolio, ranked #3436.

SBI Securities first reported a position in ACRV in Q4 2024 and has held it in 7 quarters since. The position peaked at $445 in Q4 2024. 9 funds tracked by Wall St. Rank hold ACRV as of Q2 2026.

  • SBI Securities held 75 shares of Acrivon Therapeutics worth $134 as of Q2 2026.
  • SBI Securities bought 1 Acrivon Therapeutics share in Q2 2026, an estimated $2.
  • Acrivon Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3436 holding.
  • SBI Securities first reported a position in Acrivon Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Acrivon Therapeutics position peaked at $445 in Q4 2024.
  • 9 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.